Is SOMNOLENCE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed SOMNOLENCE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 29 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported SOMNOLENCE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and SOMNOLENCE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause SOMNOLENCE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes SOMNOLENCE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if SOMNOLENCE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing SOMNOLENCE: 29
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where SOMNOLENCE is a reported side effect: 0.8711%

FDA reports of any drug causing SOMNOLENCE : 53069
Average percentage for all medicated patients where SOMNOLENCE is reported as a complication: 0.3326%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with SOMNOLENCE:

SEROQUEL (5217 patients)
LYRICA (5043 patients)
ASPIRIN (3113 patients)
NEURONTIN (2141 patients)
CHANTIX (2039 patients)
CYMBALTA (1846 patients)
RISPERDAL (1730 patients)
XANAX (1523 patients)
LIPITOR (1494 patients)
LASIX (1424 patients)
PAXIL (1408 patients)
ZYPREXA (1399 patients)
DURAGESIC-100 (1371 patients)
SYNTHROID (1350 patients)
ZOLOFT (1336 patients)
NEXIUM (1316 patients)
LORAZEPAM (1310 patients)
LISINOPRIL (1291 patients)
CLONAZEPAM (1286 patients)
OMEPRAZOLE (1281 patients)
OXYCONTIN (1214 patients)
ACETAMINOPHEN (1211 patients)
GABAPENTIN (1173 patients)
FORTEO (1116 patients)
SIMVASTATIN (1110 patients)
FUROSEMIDE (1110 patients)
ATENOLOL (1106 patients)
NAMENDA (1069 patients)
STRATTERA (1060 patients)
KLONOPIN (1056 patients)
LEVOTHYROXINE SODIUM (1047 patients)
CLOZARIL (1036 patients)
AMBIEN (1020 patients)
SEROQUEL XR (1008 patients)
LEXAPRO (997 patients)
FOSAMAX (982 patients)
FENTANYL (974 patients)
HYDROCHLOROTHIAZIDE (974 patients)
LAMICTAL (946 patients)
IBUPROFEN (945 patients)
DIAZEPAM (937 patients)
EFFEXOR (931 patients)
METFORMIN HCL (928 patients)
TEGRETOL (926 patients)
KEPPRA (906 patients)
OXYCODONE HCL (878 patients)
PLAVIX (868 patients)
MORPHINE (865 patients)
MORPHINE SULFATE (862 patients)
VIOXX (859 patients)
DEPAKOTE (834 patients)
ALPRAZOLAM (832 patients)
PREDNISONE (809 patients)
TYSABRI (795 patients)
BYETTA (791 patients)
ATIVAN (788 patients)
GEODON (776 patients)
CELEBREX (771 patients)
TOPROL-XL (748 patients)
NORVASC (747 patients)
PRILOSEC (740 patients)
TRAMADOL HCL (733 patients)
ALBUTEROL (730 patients)
ZOCOR (712 patients)
VALIUM (707 patients)
PROZAC (700 patients)
ABILIFY (698 patients)
LANTUS (695 patients)
FOLIC ACID (684 patients)
REQUIP (681 patients)
LUNESTA (674 patients)
WELLBUTRIN (669 patients)
PERCOCET (663 patients)
VITAMIN D (656 patients)
DIGOXIN (654 patients)
PREVACID (654 patients)
CRESTOR (650 patients)
DIOVAN (648 patients)
VICODIN (647 patients)
COUMADIN (645 patients)
HALDOL (642 patients)
TRILEPTAL (631 patients)
POTASSIUM CHLORIDE (615 patients)
TOPAMAX (611 patients)
CLOZAPINE (600 patients)
DEPAKENE (595 patients)
EFFEXOR XR (595 patients)
FENTANYL-100 (594 patients)
TRAZODONE HCL (591 patients)
PRISTIQ (588 patients)
CELEXA (586 patients)
AMLODIPINE (581 patients)
METHOTREXATE (571 patients)
CALCIUM (567 patients)
BACLOFEN (566 patients)
METOPROLOL TARTRATE (563 patients)
RIVOTRIL (557 patients)
PROTONIX (554 patients)
ZYRTEC (553 patients)
CITALOPRAM HYDROBROMIDE (551 patients)
SINGULAIR (549 patients)
ACCUTANE (549 patients)
LIORESAL (544 patients)
HUMIRA (543 patients)
ARICEPT (542 patients)
DEXAMETHASONE (539 patients)
ADVAIR DISKUS 100/50 (528 patients)
MIRTAZAPINE (526 patients)
CARBAMAZEPINE (522 patients)
AMITRIPTYLINE HCL (520 patients)
ALLOPURINOL (518 patients)
ZOMETA (516 patients)
VALPROATE SODIUM (511 patients)
LAMOTRIGINE (504 patients)
MIRAPEX (503 patients)
OLANZAPINE (500 patients)
BENADRYL (497 patients)
RISPERIDONE (494 patients)
AVONEX (485 patients)
PAROXETINE HCL (480 patients)
INSULIN (480 patients)
ENBREL (477 patients)
LITHIUM CARBONATE (475 patients)
CLONIDINE (473 patients)
WARFARIN SODIUM (464 patients)
RAMIPRIL (458 patients)
METHADONE HCL (456 patients)
ALL OTHER THERAPEUTIC PRODUCTS (451 patients)
PREMARIN (444 patients)
EXELON (441 patients)
ALEVE (CAPLET) (434 patients)
LORTAB (429 patients)
METFORMIN (416 patients)
COREG (412 patients)
FLUOXETINE (412 patients)
PREDNISOLONE (406 patients)
DILANTIN (405 patients)
MULTI-VITAMIN (391 patients)
ZANTAC (389 patients)
GLUCOPHAGE (388 patients)
SINEMET (376 patients)
MULTI-VITAMINS (372 patients)
SPIRIVA (367 patients)
SUBOXONE (363 patients)
SPIRONOLACTONE (357 patients)
PROVIGIL (355 patients)
PARACETAMOL (353 patients)
DECADRON (350 patients)
TYLENOL (350 patients)
VALTREX (349 patients)
ZETIA (348 patients)
TOPIRAMATE (348 patients)
FLEXERIL (344 patients)
LEVOXYL (342 patients)
TEMAZEPAM (342 patients)
PREDNISONE TAB (341 patients)
ALDACTONE (340 patients)
SOMA (339 patients)
RANITIDINE (338 patients)
VITAMIN E (338 patients)
COZAAR (336 patients)
ALCOHOL (336 patients)
XYREM (329 patients)
METOPROLOL (329 patients)
REMERON (328 patients)
ZOLPIDEM (325 patients)
LANSOPRAZOLE (325 patients)
ASCORBIC ACID (323 patients)
NITROGLYCERIN (323 patients)
GLYBURIDE (320 patients)
FLONASE (318 patients)
HALOPERIDOL (316 patients)
VITAMIN B-12 (315 patients)
TYLENOL (CAPLET) (314 patients)
ALTACE (313 patients)
VALPROIC ACID (311 patients)
FISH OIL (310 patients)
ULTRAM (309 patients)
ZOLPIDEM TARTRATE (309 patients)
SANDOSTATIN LAR (308 patients)
FENTANYL CITRATE (307 patients)
ZOFRAN (301 patients)
ALLEGRA (297 patients)
ENALAPRIL MALEATE (297 patients)
ACTOS (296 patients)
GILENYA (294 patients)
DILAUDID (293 patients)
AMARYL (292 patients)
ACETYLSALICYLIC ACID (292 patients)
HUMALOG (292 patients)
ALEVE (291 patients)
REVLIMID (290 patients)
REMICADE (289 patients)
ROZEREM (288 patients)
AMOXICILLIN (288 patients)
AVANDIA (287 patients)
VITAMINS (283 patients)
RITALIN (282 patients)
GLIPIZIDE (281 patients)
FLOMAX (277 patients)
CARVEDILOL (276 patients)
FENTANYL TRANSDERMAL SYSTEM (276 patients)
ACETYLSALICYLIC ACID SRT (272 patients)
VERAPAMIL (271 patients)
PROMETHAZINE (266 patients)
NAPROXEN (266 patients)
PHENYTOIN (265 patients)
MS CONTIN (264 patients)
METOCLOPRAMIDE (264 patients)
PROPRANOLOL (263 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about SOMNOLENCE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.